Karl Rothweiler – Startup Investor Profile

Karl Rothweiler is a Partner at Aglaia BioMedical Ventures, based in Brisbane, Australia. Aglaia invests in industries such as BioTech, FinTech, and Pharmaceutical, with an investment range from $100,000 to $5,000,000, focusing on companies like Inthera Bioscience and Cristal Therapeutics. Karl Rothweiler is a Co-Founder of Aglaia and has investments in various companies within these sectors.

Location: Netherlands

Country: Netherlands

Investment Regions: EU

Investment Stages: pre-seed, seed

Website: https://www.aglaia-oncology.com/team/

AI Reasoning: Signal/NFX shows Karl Rothweiler as Founding Investor and Member of the Supervisory Board at Inthera Bioscience AG with involvement listed as 2022 – Present. The most recent known investment activity is Inthera Bioscience in 2022; the time since that investment (from 2022 to the reference date) is more than 12 months but less than or equal to 36 months, placing him in the 12-6 months window? However, the 2022 date is over 12 months ago, which would normally be ‘low-active’. But Signal indicates ‘Present’ (ongoing supervisory role) – the last known investment involvement is listed as ongoing; the latest specific investment year (2022) is between 12 and 36 months ago, so classify as active.

Low Activity – Only known angel investments more than 12 months ago.

Active – Known angel investments between the last 12 and 6 months.

Very Active – Known angel investments in the last 6 months.